1. Home
  2. PBYI vs WNEB Comparison

PBYI vs WNEB Comparison

Compare PBYI & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • WNEB
  • Stock Information
  • Founded
  • PBYI 2010
  • WNEB 1853
  • Country
  • PBYI United States
  • WNEB United States
  • Employees
  • PBYI N/A
  • WNEB N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • WNEB Savings Institutions
  • Sector
  • PBYI Health Care
  • WNEB Finance
  • Exchange
  • PBYI Nasdaq
  • WNEB Nasdaq
  • Market Cap
  • PBYI 153.2M
  • WNEB 189.6M
  • IPO Year
  • PBYI N/A
  • WNEB N/A
  • Fundamental
  • Price
  • PBYI $3.09
  • WNEB $8.68
  • Analyst Decision
  • PBYI Strong Buy
  • WNEB Hold
  • Analyst Count
  • PBYI 1
  • WNEB 3
  • Target Price
  • PBYI $7.00
  • WNEB $8.50
  • AVG Volume (30 Days)
  • PBYI 754.5K
  • WNEB 39.5K
  • Earning Date
  • PBYI 02-27-2025
  • WNEB 01-21-2025
  • Dividend Yield
  • PBYI N/A
  • WNEB 3.23%
  • EPS Growth
  • PBYI 492.79
  • WNEB N/A
  • EPS
  • PBYI 0.47
  • WNEB 0.52
  • Revenue
  • PBYI $243,569,000.00
  • WNEB $72,500,000.00
  • Revenue This Year
  • PBYI N/A
  • WNEB N/A
  • Revenue Next Year
  • PBYI N/A
  • WNEB $6.24
  • P/E Ratio
  • PBYI $6.63
  • WNEB $16.76
  • Revenue Growth
  • PBYI 6.30
  • WNEB N/A
  • 52 Week Low
  • PBYI $2.23
  • WNEB $6.00
  • 52 Week High
  • PBYI $7.73
  • WNEB $10.08
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 49.17
  • WNEB 34.73
  • Support Level
  • PBYI $2.92
  • WNEB $8.51
  • Resistance Level
  • PBYI $4.06
  • WNEB $9.22
  • Average True Range (ATR)
  • PBYI 0.29
  • WNEB 0.18
  • MACD
  • PBYI 0.01
  • WNEB -0.08
  • Stochastic Oscillator
  • PBYI 27.07
  • WNEB 20.24

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.

Share on Social Networks: